Exosla Therapeutics

Executive Summary

Exosla Therapeutics is a German preclinical-stage biotechnology company pioneering immune-modulatory, off-the-shelf restorative medicines for neonatal neurological disorders. Founded in 2021 and based in Munich, the company focuses on developing multimodal signalling approaches that harness the body's own immune system to promote tissue repair and neuroprotection. Its lead program targets hypoxic-ischemic encephalopathy (HIE) in newborn infants, a condition with high unmet medical need and limited treatment options. Exosla's technology leverages allogeneic, off-the-shelf cell-based or exosome-based therapies designed to modulate multiple immune pathways simultaneously, improving upon single-target approaches that have shown limited efficacy. By addressing challenges in manufacturing, quality control, and batch-to-batch consistency, Exosla aims to deliver a readily available treatment that can be administered in critical care settings. The company is currently in preclinical development, focusing on completing proof-of-concept studies and advancing toward IND-enabling activities. Given the strong scientific rationale and the urgent need for effective HIE therapies, Exosla represents an attractive early-stage opportunity in neuroimmunology.

Upcoming Catalysts (preview)

• Q3 2026Preclinical Efficacy Data Readout in HIE Model70% success
• Q4 2026IND Submission for Lead Candidate40% success
• Q3 2026Series A Financing Announcement60% success